Review for 10.1186/s12876-017-0633-6 (2017)

Reviewer ’s report  
 
Title: Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with 
ustekinumab: case -report and review of the literature  
 
Version: 0 Date: 14 Mar 2017  
 
Reviewer: Vivian Huang  
 
Reviewer's report:  
 
An importan t discussion of "safety" of ustekinumab, and the lack of true data.   Please consider 
including the recently published article  
J Clin Pharm Ther. 2017 Apr;42(2):234 -236. doi: 10.1111/jcpt.12492. Epub 2016 Dec 22.  
Ustekinumab therapy for Crohn's disease dur ing pregnancy: a case report and review of the 
literature.  
Cortes X1, Borrás -Blasco J2, Antequera B3, Fernandez -Martinez S4, Casterá E2, Martin S5, 
Molés JR1.  
Are the methods appropriate and well described?  
If not, please specify what is required i n your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Unable to assess  
 
Are the conclusions drawn adequately supported by the data shown?  
If not,  please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require fu rther  
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publi cation of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you curr ently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any  other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
Have received honorarium for advisory board, consultation fees, unrestricted educational 
sponsorship grants - from Janssen, Abbvie, Takeda (the other biologic companies for IBD 
medications)  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comme nts 
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal